Stimulation of P2Y1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: Implications for the involvement of P2Y1 receptor-mediated nitric oxide production

Neuropsychopharmacology

Volumn 28, Issue 3, 2003, Pages 3-435

  Kittner, Holger ^a   Franke, Heike ^a   Fischer, Wolfgang ^a   Schultheis, Nina ^a   Krügel, Ute ^a   Illes, Peter ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Anxiety; MRS 2179; Nitric oxide; P2 purinoceptors; Plus maze; PPADS

Indexed keywords

ENZYME INHIBITOR; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOS1 PROTEIN, RAT; PURINE P2 RECEPTOR; PURINE P2Y1 RECEPTOR;

ANIMAL; ANXIETY; ARTICLE; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HYPOTHALAMUS NUCLEUS; MALE; MAZE TEST; METABOLISM; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; ANXIETY; DORSOMEDIAL HYPOTHALAMIC NUCLEUS; ENZYME INHIBITORS; MALE; MAZE LEARNING; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2;

EID: 84984930123     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300043     Document Type: Article

References (65)

1. Alderton WK, Cooper CE, Knowles RG (2001). Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615.
2. Bogdanov YD, Wildman SS, Clements MP, King BF, Burnstock G (1998).Molecular cloning and characterization of rat P2Y4 nucleotide receptor. Br J Pharmacol 124: 428-430.
3. Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK (1998). Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol 124: 1-3.
4. Boyer JL, Zohn IE, Jacobson KA, Harden TK (1994). Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol 113: 614-620.
5. Bürnstock G (2001). Purine-mediated signalling in pain and visceral perception. Trends PharmacolSci 22: 182-188.
6. Castagnoli K, Palmer S, Anderson A, Bueters T, CastagnoliJr N (1997). The neuronal nitric oxide synthase inhibitor 7-nitroin-dazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 10: 364-368.
7. Caton PW, Tousman SA, Quock RM (1994).Involvement of nitric oxide in nitrous oxide anxiolysis in the elevated plus-maze. PharmacolBiochemBehav 48: 689-692.
8. Chan CF, Lin-Shiau SY (2001). Suramin prevents cerebellar granule cell-death induced by dequalinium. NeurochemInt 38: 135-143.
9. Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder MR (1996). PPADS and suramin as antagonists at cloned P2Y-and P2U-purinoceptors. Br J Pharmacol 118: 704-710.
10. Chikada N, Imaki T, Seki T, Harada S, Nakajima K, Yoshimoto T et al (2000). Distribution of c-fos mRNA in the brain following intracerebroventricular injection of nitric oxide (NO)-releasing compounds: possible role of NO in central cardiovascular regulation. J Neuroendocrinol 12: 1112-1123.
11. 11 receptor. Br J Pharmacol 128: 1199-1206.
12. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD (1995). Evidence that the anxiolytic-like effects of chlor-diazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berl) 118: 316-323.
13. De Oliveira CL, Del Bel EA, Guimaraes FS (1997).Effects of l-NOARG on plus-maze performance in rats. Pharmacol BiochemBehav 56: 55-59.
14. Dol-Gleizes F, Mares AM, Savi P, Herbert JM (1999). Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel. Eur J Pharmacol 367: 247-253.
15. File SE (1991). The biological basis of anxiety. In: Meltzer, Y, Nerozzi, D (eds). Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders.ExcerptaMedica: Amsterdam. pp 159-166.
16. File SE, Gonzalez LE, Andrews N (1998). Endogenous acetylcholine in the dorsal hippocampus reduces anxiety through actions on nicotinic and muscarinic1 receptors. BehavNeurosci 112: 352-359.
17. File SE, Kenny PJ, Cheeta S (2000). The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. PharmacolBiochemBehav 66: 65-72.
18. Franke H, Krügel U, Schmidt R, Grosche J, Reichenbach A, Illes P (2001). P2 receptor involved in astrogliosis in vivo. Br J Pharmacol 134: 1180-1189.
19. Frisch C, Dere E, Silva MA, Godecke A, Schrader J, Huston JP (2000). Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebel-lum and ventral striatum. J Neurosci 20: 6694-6700.
20. Fröhlich R, Boehm S, Illes P (1996). Pharmacological characterization of P2 purinoceptor types in rat locus coeruleus neurons. Eur J Pharmacol 315: 255-261.
21. Greenberg JH, Hamada J, Rysman K (1997). Distribution of N(omega)-nitro-L-arginine following topical and intracerebroventricular administration in the rat. NeurosciLett 229: 1-4.
22. Griebel G, Curet O, Perrault G, Sanger DJ (1998). Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamineoxidase activity and monoamine levels.Neuropharmacology 37: 927-935.
23. Gu JG, Bardoni R, Magherini PC, MacDermott AB (1998). Effects of the P2-purinoceptor antagonists suramin and pyridoxal-phos-phate-6-azophenyl-2',4'-disulfonic acid on glutamatergicsynap-tic transmission in rat dorsal horn neurons of the spinal cord. NeurosciLett 253: 167-170.
24. Guimaraes FS, de Aguiar JC, Del Bel EA, Ballejo G (1994).Anxiolytic effect of nitric oxide synthase inhibitors microin-jected into the dorsal central grey. Neuroreport 5: 1929-1932.
25. Hamada J, Greenberg JH, Croul S, Dawson TM, Reivich M (1995).Effects of central inhibition of nitric oxide synthase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 15: 779-786.
26. Handley SL, Mithani S (1984). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedebergs Arch Pharmacol 327: 1-5.
27. Hu XT, Wang RY (1988). Disinhibition of nucleus acc-umbens neurons by the dopamine D2 receptor agonist LY 141865: prevented by 6-OHDA pretreatment. Brain Res 444: 389-393.
28. Inglefield JR, Schwarzkopf SB, Kellogg CK (1994). Alterations in behavioral responses to stressors following excitotoxin lesions of dorsomedial hypothalamic regions. Brain Res 633: 151-161.
29. Kalynchuk LE, Pinel JP, Treit D, Barnes SJ, McEachern JC, Kippin TE (1998). Persistence of the interictal emotionality produced by long-term amygdala kindling in rats. Neuroscience 85: 1311-1319.
30. Keim SR, Shekhar A (1996). The effects of GABAA receptor blockade in the dorsomedial hypothalamic nucleus on cortico-trophin (ACTH) and corticosterone secretion in male rats. Brain Res 739: 46-51.
31. Kennedy C, Leff P (1995). How should P2X purinoceptors be classified pharmacologically? Trends PharmacolSci 16: 168-174.
32. Kittner H, Krügel U, Illes P (1997). 2-Methylthio ATP (2-MeSATP) enhances dopaminergic mechanisms in the mesolimbic meso-cortical system of the rat: an in vivo study. Naunyn-Schmiede-bergs Arch Pharmacol 356(Suppl 1), R52.
33. Kittner H, Krügel U, Illes P (2001). The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. Neuroscience 102: 241-243.
34. Krügel U, Kittner H, Franke H, Illes P (2001a). Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo. Neuropharmacology 40: 1084-1093.
35. Krügel U, Regenthal R, Kittner H, Illes P (2001b). P2 receptor stimulation facilitates glutamate release in the nucleus accum-bens. In: Elsner, N, Kreutzberg, GW (ed.). G. ThiemeVerlag, Stuttgart. p 64.
36. Liu JS, John GR, Sikora A, Lee SC, Brosnan CF (2000). Modulation of interleukin-1β and tumor necrosis factor alpha signaling by P2 purinergic receptors in human fetal astrocytes. J Neurosci 20: 5292-5299.
37. Malmsjö M, Erlinge D, Hogestatt ED, Zygmunt PM (1999). Endothelial P2Y receptors induce hyperpolarisation of vascular smooth muscle by release of endothelium-derived hyperpolarising factor. Eur J Pharmacol 364: 169-173.
38. Monzon ME, Varas MM, De Barioglio SR (2001). Anxiogenesis induced by nitric oxide synthase inhibition and anxiolytic effect of melanin-concentrating hormone (MCH) in rat brain. Peptides 22: 1043-1047.
39. Moore D, Chambers J, Waldvogel H, Faull R, Emson P (2000). Regional and cellular distribution of the P2Y1 purinergic receptor in the human brain: striking neuronal localisation. J Comp Neurol 421: 374-384.
40. Motin L, Bennett MR (1995). Effect of P2-purinoceptor antagonists on glutamatergic transmission in the rat hippocampus. Br J Pharmacol 115: 1276-1280.
41. 12 receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides. MolPharmacol 60: 416-420.
42. Nörenberg W, Illes P (2000). Neuronal P2X receptors: localisation and functional properties. Naunyn-Schmiedebergs Arch Pharma-col 362: 324-339.
43. Paxinos G, Watson CH (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
44. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
45. Petrovich GD, Risold PY, Swanson LW (1996). Organization of projections from the basomedial nucleus of the amygdala: a PHAL study in the rat. J Comp Neurol 374: 387-420.
46. Quock RM, Nguyen E (1992). Possible involvement of nitric oxide in chlordiazepoxide-induced anxiolysis in mice. Life Sci 51: PL255-PL260.
47. Ralevic V, Burnstock G (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492.
48. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752.
49. Reiser G (1995). Ca(2+)- and nitric oxide-dependent stimulation of cyclic GMP synthesis in neuronal cell line induced by P2-purinergic/pyrimidinergic receptor. J Neurochem 64: 61-68.
50. Royland JE, Delfani K, Langston JW, Janson AM, Di Monte DA (1999). 7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Res 839: 41-48.
51. Rump LC, Oberhauser V, von Kügelgen I (1998).Purinoceptors mediate renal vasodilation by nitric oxide dependent and independent mechanisms. Kidney Int 54: 473-481.
52. Salter M, Duffy C, Garthwaite J, Strijbos PJ (1995).Substantial regional and hemispheric differences in brain nitric oxide synthase (NOS) inhibition following intracerebroventricular administration of N omega-nitro-L-arginine (l-NA) and its methyl ester (l-NAME). Neuropharmacology 34: 639-649.
53. Schmidt WJ, Kretschmer BD (1997). Behavioural pharmacology of glutamate receptors in the basal ganglia. NeurosciBiobehav 21: 381-392.
54. Shekhar A, Keim SR (1997). The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder. J Neurosci 17: 9726-9735.
55. Treit D, Menard J (1997). Dissociations among the anxiolytic effects of septal, hippocampal, and amygdaloid lesions. Behav Neurosci 111: 653-658.
56. Vale AL, Green S, Montgomery AM, Shafi S (1998). The nitric oxide synthesis inhibitor L-NAME produces anxiogenic-like effects in the rat elevated plus-maze test, but not in the social interaction test. J Psychopharmacol 12: 268-272.
57. Vanhatalo S, Soinila S (1998). Serotonin is not synthesized, but specifically transported in the neurons of the hypothalamic dorsomedial nucleus. Eur J Neurosci 10: 1930-1935.
58. Vigne P, Pacaud P, Urbach V, Feolde E, Breittmayer JP, Frelin C (1996). The effect of PPADS as an antagonist of inositol (1,4,5) trisphosphate induced intracellular calcium mobilization. Br J Pharmacol 119: 360-364.
59. Vöhringer C, Schäfer R, Reiser G (2000). A chimeric rat brain P2Yj receptor tagged with green-fluorescent protein: high-affinity ligand recognition of adenosine diphosphates and triphosphates and selectivity identical to that of the wild-type receptor. BiochemPharmacol 59: 791-800.
60. Volke V, Koks S, Vasar E, Bourin M, Bradwejn J, Mannisto PT (1995). Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Neuroreport 6: 1413-1416.
61. Volke V, Soosaar A, Koks S, Bourin M, Mannisto PT, Vasar E (1997). 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) 131: 399-405.
62. Windscheif U, Pfaff O, Ziganshin AU, Hoyle CH, Baumert HG, Mutschler E et al (1995). Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum.Br J Pharmacol 115: 1509-1517.
63. Xu ZQ, de Vente J, Steinbusch H, Grillner S, Hökfelt T (1998). The NO-cGMP pathway in the rat locus coeruleus: electrophysiolo-gical, immunohistochemical and in situ hybridization studies. Eur J Neurosci 10: 3508-3516.
64. Yildiz F, Ulak G, Erden BF, Gacar N (2000). Anxiolytic-like effects of 7-nitroindazole in the rat plus-maze test. PharmacolBiochem Behav 65: 199-202.
65. You J, Johnson TD, Childres WF, Bryan RM Jr.(1997).Endothelialmediated dilations of rat middle cerebral arteries by ATP and ADP. Am J Physiol 273: H1472-H1477.